Scientific Publications

To date, over 75 worldwide discovery, translational or validation studies have used GU BioBank specimens and/or data, some of them resulting in publications in high impact specialty journals. A sample of the published articles and abstracts can be found below.

  1. Scientists report genetic test to help predict men at most risk from aggressive prostate cancer. ScienceDaily.  https://www.sciencedaily.com/releases/2017/03/170327083451.htm. Accessed March 30, 2017.
  2. Olkhov-Mitsel E, Siadat F, Kron K, Liu L, Savio AJ, Trachtenberg J, Fleshner N, van der Kwast T, Bapat B. Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. Oncol Letters. 2017, in press.
  3. Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe V, Hermanns T, Fleshner NE, van Rhijn BW, van der Kwast TH, Zlotta AR, Bapat B. Epigenome-wide DNA methylation profiling identifies differential methylation biomarkers in high-grade bladder cancer. Transl Oncol. 2017;10(2):168-177.
  4. Mora BC, Fleshner NE, Klotz LH, Venkateswaran V. The effects of serum from prostate cancer patients with elevated body mass index on prostate cancer cells in vitro. Lipid Insights. 2015;8:11-19. doi:10.4137/LPI.S23135.
  5. Kader AK, Liss MA, Trottier G, et al. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk. Urology. 2015;85(1):165-170. doi:10.1016/j.urology.2014.07.081.
  6. White-Al Habeeb NMA, Ho LT, Olkhov-Mitsel E, Kron K, Pethe V, Lehman M, Jovanovic L, Fleshner N, van der Kwast T, Nelson CC, Bapat B. Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. Oncotarget. 2014;5(17):7858-7869.
  7. Olkhov-Mitsel E, Zdravic D, Kron K, van der Kwast T, Fleshner N, Bapat B. Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids. Sci Rep. 2014;4:4432.
  8. Briollais L, Xu J, Kwiatkowski M, et al. MP49-20 fine-mapping of the kallikrein region and its role in prostate cancer aggressiveness: results from a Canadian cohort and the European randomized study for prostate cancer screening. The Journal of Urology. 2014;191(4):e509. doi:10.1016/j.juro.2014.02.1121.
  9. Bhindi B, Margel D, Hamilton RJ, et al. The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. Urology. 2014;84(5):1073-1080. doi:10.1016/j.urology.2014.05.071.
  10. Bhindi B, Kulkarni GS, Finelli A, et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol. 2014;66(5):841-848. doi:10.1016/j.eururo.2014.06.005.
  11. Novak A, Binnington B, Ngan B, Chadwick K, Fleshner N, Lingwood CA. Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies. Glycobiology. 2013;23(11):1230-1239. doi:10.1093/glycob/cwt059.
  12. Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, Bapat B. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin Cancer Res. 2013;19(13):3450-3461.
  13. Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, Bapat B, van der Kwast T. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res. 2012;18(10):2896-2904.
  14. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012;187(1):310-314.
  15. Olkhov-Mitsel E, van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, Recker F, Kwiatkowski M, Fleshner NE, Diamandis EP, Zlotta AR, Bapat B. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics. 2012;7(9):1037-1045.
  16. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH, Bapat B. Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer. 2011;129(10);2454-2462.
  17. Kron KJ, Liu L, Pethe V, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH, Bapat B. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest. 2010;90(7):1060-1067.
  18. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T, Bapat B. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One. 2009;4(3):e4830.